Politicians urge Obama to allow public review of IP provisions in TPP

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Politicians urge Obama to allow public review of IP provisions in TPP

Six members of US Congress have written to US President Barack Obama expressing concern that "secret" negotiations over intellectual property in the Trans Pacific Partnership (TPP) Agreement benefit pharmaceutical companies at the expense of public health.

The six Democrats - Jan Schakowsky (Illonois), Michael Michaud (Maine), Rosa DeLauro (Conneticut), George Miller (California), Barbara Lee (California) and Peter Welch (Vermont) - said the current proposals would have "profound and long-lasting consequences".

In the letter, sent yesterday, the Members urged Obama not to make any final trade agreements "that affect critical health issues" until members of the public and Congress have had the opportunity to review the provisions and provide input.

In particular, they argued that proposed provisions relating to data exclusivity, patent registration and procedure and enforcement would "delay generic competition and increase the price of medicine" and lead to "preventable illnesses and deaths".

"Certainly, trade negotiations conducted behind closed doors are not the place to make changes that would have such profound consequences for patents and veterans, as well as state and federal budgets," they wrote.

Although the TPP negotiations were meant to have been conducted in secret, whistleblowing website WikiLeaks has released several documents which suggest the US is exerting "great pressure" on other nations to adopt stricter IP policies. In the latest release, yesterday, WikiLeaks published two leaked documents that suggest that the US is isolated in its positions on many IP policies.

more from across site and SHARED ros bottom lb

More from across our site

Submit your nominations to this year's WIBL Americas Awards by January 23
The 2026 Life Sciences EMEA Awards is now open for entries. We are looking forward to reviewing and celebrating the industry's most impressive achievements and landmarks from the past year.
The tie-up between Perkins Coie and Ashurst may generate some striking numbers, but independent IP firms need not worry yet, according to practitioners
Perkins Coie’s US patent prosecution strength could provide Ashurst with an opportunity to enter an untapped market in Australia, but it may not be easy
Mitesh Patel at Reed Smith outlines why the US Copyright Office and courts have so far dismissed AI authorship and how inventors can protect AI-generated works
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
A dispute involving semiconductor technology and a partner's move from Hoffman Eitle to Hoyng Rokh Monegier were also among the top talking points
A former Freshfields counsel and an ex-IBM counsel, who have joined forces at law firm Caldwell, say clients are increasingly sophisticated in their IP demands
Daniel Raymond, who will serve as head of client relations, tells Managing IP that law firms must offer ‘brave’ opinions if they want to keep winning new business
The new outfit, Ashurst Perkins Coie, will bring together around 3,000 lawyers across 23 countries
Gift this article